Everything practicing physicians and pharmacists need to know about drug therapy for cardiovascular disease.

A critically acclaimed classic reference now in its third edition, Cardiovascular Pharmacotherapeutics provides current information regarding the contemporary use of all available cardiovascular medications for adults and children. Strongly emphasizing the scientific rationale behind the use of such therapies in cardiac disease, it discusses new drugs and novel compounds that are under development and may emerge as the cardiac therapies of the future. This edition also addresses special considerations for drug therapy use in the elderly, during pregnancy, and in those with hepatic or renal disease. A generous assortment of tables, figures, and appendices guides readers in their investigations of each drug group and various disease states.

This new third edition presents an in-depth discussion of:

• All cardiovascular agents currently available
• The scientific basis behind every pharmacotherapy advance
• Mechanisms of action of cardiovascular pharmacotherapeutics
• The latest advances in cardiovascular drug therapy
• Specific drug treatments, and information on recently approved drugs
• Molecular biological advances
• Drugs in development
• Hands-on discussions of how to utilize specific drugs for treatment of various cardiovascular disorders and for the prevention of disease

Also included are 8 appendices that provide practical, hands-on information on using drugs in clinical settings, including relevant pharmacokinetic information, and practical drug prescribing information.

All updated with an accompanying website, Advances in Cardiovascular Pharmacotherapeutics www.cvpct3.com

Authors:

Co-editors and co-authors William H. Frishman, MD, and Domenic A. Sica, MD, are distinguished physician-scientists with important research accomplishments in cardiovascular pharmacology and pathophysiology. Also included are contributions from many of the leading investigators in cardiovascular pathophysiology and drug development.

Contents:

This edition is organized into 4 main sections.

1. The introductory section includes chapters related to relevant clinical pharmacology, the placebo effect in cardiovascular disease treatments, patient adherence to pharmacotherapy, and pharmacoeconomics.
2. The available cardiovascular drugs are reviewed, and each class of drugs is organized into separate chapters. In these chapters the reader will find detailed discussions on how to use individual drugs for prevention and treatment. New drugs in development for each class of agents are also reviewed. Compared to the first 2 editions, the editors have provided hundreds of updated reference citations, as well as adding new chapters on drugs for pulmonary hypertension, vasopressin and vasopressin antagonists, and drug-eluting stents. Since cardiovascular clinicians do not practice in a vacuum, there are also chapters in this section that deal with the pharmacotherapy of obesity, diabetes mellitus, and smoking cessation as it relates to the cardiac patient.
3. Special topics related to cardiovascular pharmacotherapy that the clinician will often encounter and includes chapters on alternative and complementary medicine, cardiovascular drug-drug interactions, pediatric cardiovascular pharmacology, antibiotic prophylaxis and treatment guidelines for endocarditis and rheumatic fever, and drug therapy of cerebrovascular and peripheral vascular diseases. The section concludes with a chapter on cytokines and myocardial regeneration as a new therapeutic option for cardiac disease and a final chapter that summarizes the status of more than 200 agents that are currently in clinical trials as innovative treatments for cardiovascular disease.
4. 8-part appendix provides practical, hands-on information on using drugs in clinical settings.
   • Provides relevant pharmacokinetic information regarding all the available cardiovascular drugs.
   • Offers practical drug prescribing information.
   • Guides for using cardiovascular drugs in specific patient populations.

This book features an accompanying website, Advances in Cardiovascular Pharmacotherapeutics (www.cvpct3.com), which highlights advances in cardiovascular drug therapy. Each chapter in the book is updated periodically online with links to new studies; the original chapter authors oversee the updates. In addition, new cardiovascular drugs approved for clinical use by the FDA are reviewed. Readers may communicate directly with the authors and editors through the website regarding topics related to cardiovascular drug use.

Note that bibliographic references are not listed in the book but available online in the form of downloadable PDFs at www.cvpct3.com.

Part 1: Introduction


1. Basic Principles of Clinical Pharmacology Relevant to Cardiology
William H. Frishman

2. The Placebo Effect in the Treatment of Cardiovascular Disease
William H. Frishman and Stephen P. Glasser

3. Importance of Medication Adherence in Cardiovascular Disease Treatment
William H. Frishman and Renée J. G. Arnold

4. Health Economic Considerations in Cardiovascular Drug Utilization
Renée J. G. Arnold and William H. Frishman


Part 2: Drug Classes


5. Alpha- and Beta-Adrenergic Blocking Drugs
William H. Frishman

6. Central and Peripheral Sympatholytics
Lawrence R. Krakoff and William H. Frishman

7. Cholinergic and Anticholinergic Drugs
B. Robert Meyer and William H. Frishman

8. Calcium Channel Blockers
William H. Frishman and Domenic A. Sica

9. The Renin Angiotensin Axis: Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
Domenic A. Sica, Todd W. B. Gehr, and William H. Frishman

10. The Renin Angiotensin Axis: Direct Renin Inhibition
William H. Frishman and Domenic A. Sica

11. Diuretic Therapy in Cardiovascular Disease
Domenic A. Sica, Todd W. B. Gehr, and William H. Frishman

12. Magnesium, Potassium, and Calcium as Cardiovascular Disease Therapies
Domenic A. Sica and William H. Frishman

13. Inotropic Agents
Thierry H. LeJemtel, Marc Klapholz, and William H. Frishman

14. The Organic Nitrates and Nitroprusside
Jonathan Abrams and William H. Frishman

15. Ranolazine: A Piperazine Derivative
William H. Frishman, James J. Nawarskas, and Joe R. Anderson

16. Nonspecific Antihypertensive Vasodilators
Lawrence R. Krakoff and William H. Frishman

17. Antiarrhythmic Drugs
Peter Zimetbaum, Peter R. Kowey, and Eric L. Michelson

18. Antiplatelet and Other Antithrombotic Drugs
William H. Frishman, Robert G. Lerner, and Harit Desai

19. Thrombolytic Agents
Robert Forman and William H. Frishman

20. Lipid-Lowering Drugs
William H. Frishman and Wilbert S. Aronow

21. New Aspects of Combination Therapy: Focus on Hypertension
Michael A. Weber

22. Pharmacotherapy for Smoking Cessation
William H. Frishman

23. Pharmacotherapy of Obesity
William H. Frishman, Harriette R. Mogul, and Stephen J. Peterson

24. Heart Disease and Treatment of Diabetes Mellitus
Irene A. Weiss, Guy Valiquette, Monica D. Schwarcz, and William H. Frishman

25. Prostacyclins, Endothelin Inhibitors, and Phosphodiesterase-5 Inhibitors in Pulmonary Hypertension
Warren D. Rosenblum and William H. Frishman

26. Selective and Non-selective Dopamine Receptor Agonists
William H. Frishman and Chandrasekar Palaniswamy

27. Natriuretic Peptides: Nesiritide
William H. Frishman and Domenic A. Sica

28. Vasopressin and Vasopressin Receptor Antagonists
William H. Frishman, Marc Klapholz, Gerard Oghlakian, and Jacqueline M. Cook

29. Drug-Eluting Stents
James J. Nawarskas and Mark J. Ricciardi


Part 3: Special Topics


30. Alternative and Complementary Medicine for Preventing and Treating Cardiovascular Disease
William H. Frishman

31. Cardiovascular Drug–Drug Interactions
Angela Cheng-Lai, James J. Nawarskas, and William H. Frishman

32. Pediatric Cardiovascular Pharmacology
Michael Gewitz, Paul Woolf, and William H. Frishman

33. Drug Therapy of Neurovascular Disease
Jesse Weinberger, William H. Frishman, and Harit Desai

34. Drug Treatment of Peripheral Vascular Disorders
Veerendra Chadachan and Robert T. Eberhardt

35. Drug Treatment and Prevention of Infective Endocarditis and Rheumatic Fever
Michael Gewitz and William H. Frishman

36. Cytokines and Myocardial Regeneration: A Novel Therapeutic Option for Acute Myocardial Infarction
William H. Frishman, Guruprasad Srinivas, and Piero Anversa

37. Cardiovascular Drugs in Development
William H. Frishman and Kalyana Pallerla


Part 4: Appendices


Angela Cheng-Lai and William H. Frishman

1. Pharmacokinetic Properties of Approved Cardiovascular Drugs
2. Therapeutic Use of Available Cardiovascular Drugs
3. Guide to Cardiovascular Drug Use in Pregnancy and with Nursing
4. Dosing Recommendations of Cardiovascular Drugs in Patients with Hepatic Disease and/or
Congestive Heart Failure
5. Dose Adjustment in Patients with Renal Insufficiency
6. Selected Cardiovascular Medications and Gender Issues
7. Pharmacokinetic Changes, Route of Elimination, and Dosage Adjustment of Selected
Cardiovascular Drugs in the Elderly
8. Selected Cardiovascular Medications and Ethnic Issues

Index

Contributors

Jonathan Abrams, MD
Department of Medicine Division of Cardiology University of New Mexico Health Sciences Center Albuquerque, NM

Joe R. Anderson, PharmD
College of Pharmacy and School of Medicine The University of New Mexico Health Sciences Center Albuquerque, NM

Piero Anversa, MD
Departments of Anesthesiology and Medicine Harvard University School of Medicine Brigham and Women’s Hospital Boston, MA

Renée J. G. Arnold, RPh, PharmD
Department of Preventive Medicine Mount Sinai School of Medicine New York, NY Division of Social and Administrative Sciences Arnold and Marie Schwartz College of Pharmacy Long Island University Brooklyn, NY

Wilbert S. Aronow, MD
Department of Medicine Division of Cardiology New York Medical College Westchester Medical Center Valhalla, NY

Veerendra Chadachan, MD
Vascular Medicine Program, Boston University Medical Center Boston, MA

Angela Cheng-Lai, PharmD
Department of Pharmacy Montefiore Medical Center Department of Medicine Albert Einstein College of Medicine Bronx, NY

Jacqueline M. Cook, MD
Department of Medicine Yale University School of Medicine Yale-New Haven Hospital New Haven, CT

Harit Desai, MD
Department of Medicine New York Medical College Westchester Medical Center Valhalla, NY

Robert T. Eberhardt, MD
Department of Medicine Section of Cardiovascular Medicine Medical Vascular Services Boston University School of Medicine Boston, MA

Robert Forman, MD
Department of Medicine Division of Cardiology Albert Einstein College of Medicine Montefiore Medical Center Bronx, NY

William H. Frishman, MD
Departments of Medicine and Pharmacology New York Medical College Westchester Medical Center Valhalla, NY

Todd W. B. Gehr, MD
Department of Medicine Division of Nephrology Virginia Commonwealth University Richmond, VA

Michael Gewitz, MD
Department of Pediatrics Division of Pediatric Cardiology New York Medical College Maria Fareri Children’s Hospital Westchester Medical Center Valhalla, NY

Stephen P. Glasser, MD
Departments of Preventive Medicine and Epidemiology University of Alabama at Birmingham Birmingham, AL

Marc Klapholz, MD
Department of Medicine Division of Cardiology UMDNJ-New Jersey Medical School Newark, NJ

Peter R. Kowey, MD
Department of Medicine Division of Cardiology Jefferson Medical College Philadelphia, PA Lankenau Hospital and Main Line Health System Wynnewood, PA

Lawrence R. Krakoff, MD
Department of Medicine Cardiovascular Institute, Hypertension Program Mount Sinai Medical Center New York, NY

Thierry H. LeJemtel, MD
Department of Medicine Division of Cardiology Tulane University School of Medicine New Orleans, LA

Robert G. Lerner, MD
Department of Medicine Division of Hematology/Hemostasis New York Medical College Westchester Medical Center Valhalla, NY

B. Robert Meyer, MD
Department of Medicine Weill Cornell Medical College New York Presbyterian Hospital New York, NY

Eric L. Michelson, MD
AstraZeneca LP Wilmington, DE Jefferson Medical College Philadelphia, PA

Harriette R. Mogul, MD
Department of Medicine Division of Endocrinology New York Medical College Westchester Medical Center Valhalla, NY

James J. Nawarskas, PharmD
Department of Pharmacy Practice & Administrative Sciences University of New Mexico College of Pharmacy University of New Mexico Health Sciences Center Albuquerque, NM

Gerard Oghlakian, MD
Department of Cardiovascular Medicine Harrington and McLaughlin Heart and Vascular Institute University Hospitals Case Medical Center Case Western Reserve University Cleveland, OH

Chandrasekar Palaniswamy, MD
Department of Medicine New York Medical College Westchester Medical Center Valhalla, NY

Kalyana Pallerla, MD
Department of Medicine New York Medical College Mount Vernon Hospital Mount Vernon, NY

Stephen J. Peterson, MD
Departments of Medicine and Pharmacology New York Medical College Westchester Medical Center Valhalla, NY

Mark J. Ricciardi, MD
Department of Internal Medicine Division of Cardiology University of New Mexico Health Sciences Center Albuquerque, NM

Warren D. Rosenblum, MD
Department of Medicine Division of Cardiology New York Medical College Westchester Medical Center Valhalla, NY

Monica D. Schwarcz, MD
Department of Medicine, Division of Endocrinology New York Medical College Westchester Medical Center Valhalla, NY

Domenic A. Sica, MD
Departments of Medicine and Pharmacology Virginia Commonwealth University Richmond, VA

Guruprasad Srinivas, MD
Department of Medicine Albert Einstein College of Medicine Montefiore Medical Center Bronx, NY

Guy Valiquette, MD
Department of Medicine Division of Endocrinology New York Medical College Westchester Medical Center Valhalla, NY

Michael A. Weber, MD
Department of Medicine Division of Cardiology State University of New York Downstate College of Medicine Brooklyn, NY

Jesse Weinberger, MD
Department of Neurology The Mount Sinai School of Medicine New York, NY

Irene A. Weiss, MD
Department of Medicine Division of Endocrinology New York Medical College Westchester Medical Center Valhalla, NY

Paul Woolf, MD
Department of Pediatrics Division of Pediatric Cardiology New York Medical College Maria Fareri Children’s Hospital at Westchester Medical Center Valhalla, NY

Peter Zimetbaum, MD
Department of Medicine Cardiovascular Division Harvard University School of Medicine Beth Israel Deaconess Medical Center Boston, MA

William H. Frishman, MD, MACP; Barbara and William Rosenthal Professor of Medicine, Department of Medicine Chairman, and Professor of Pharmacology, New York Medical College; Director of Medicine, Westchester Medical Center, Valhalla, New York

Domenic A. Sica, MD; Professor of Medicine and Pharmacology, Chairman, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University